Temple Therapeutics develops novel therapies and biomarker tests targeting tissue fibrosis, endometriosis, and ovarian cancer, utilizing a unique cellular metabolism approach. The company addresses the lack of effective treatment options for patients in underserved populations suffering from these painful conditions.
Funding
$325K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of individuals, particularly women in underserved populations, suffer from tissue fibrosis, endometriosis, and ovarian cancer, often lacking effective treatment options and facing delayed or inaccurate diagnoses. Current diagnostic and therapeutic approaches often fail to address the underlying cellular metabolic dysregulation contributing to these conditions.
Solution
Temple Therapeutics is developing a pipeline of diagnostic and therapeutic candidates that target cellular metabolism to address tissue fibrosis, endometriosis, and ovarian cancer. Their approach focuses on identifying and modulating key metabolic pathways involved in disease progression, leading to novel therapies and early diagnostic tools. The company's lead candidates, TTX333 and TTX330, are being developed for tissue fibrosis and endometriosis, while a non-invasive biomarker test aims to detect ovarian tumors at earlier stages. By leveraging a deep understanding of cellular metabolism, Temple Therapeutics seeks to improve patient outcomes and provide more effective solutions for these challenging conditions.
Target Audience
The primary target audience includes women suffering from tissue fibrosis, endometriosis, and ovarian cancer, as well as the medical practitioners who treat these conditions, particularly in underserved populations.
Features
- TTX333 and TTX330: Drug candidates targeting tissue fibrosis and endometriosis, designed to inhibit fibrotic tissue growth.
- Non-invasive biomarker test for early detection of ovarian tumors.
- Diagnostic biomarker panels for earlier detection of endometriosis.
- Focus on underserved populations and addressing disparities in healthcare.
- Synergistic pipeline of diagnostic and drug candidates.
- Modulation of cellular metabolism to treat the underlying causes of disease.